Suppr超能文献

慢性阻塞性肺疾病中的心脏疾病

Cardiac disease in chronic obstructive pulmonary disease.

作者信息

Falk Jeremy A, Kadiev Steven, Criner Gerard J, Scharf Steven M, Minai Omar A, Diaz Philip

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, for the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

出版信息

Proc Am Thorac Soc. 2008 May 1;5(4):543-8. doi: 10.1513/pats.200708-142ET.

Abstract

The cardiac manifestations of chronic obstructive pulmonary disease (COPD) are numerous. Impairments of right ventricular dysfunction and pulmonary vascular disease are well known to complicate the clinical course of COPD and correlate inversely with survival. The pathogenesis of pulmonary vascular disease in COPD is likely multifactorial and related to alterations in gas exchange and vascular biology, as well as structural changes of the pulmonary vasculature and mechanical factors. Several modalities currently exist for the assessment of pulmonary vascular disease in COPD, but right heart catheterization remains the gold standard. Although no specific therapy other than oxygen has been generally accepted for the treatment of pulmonary hypertension in this population, there has been renewed interest in specific pulmonary vasodilators. The coexistence of COPD and coronary artery disease occurs frequently. This association is likely related to shared risk factors as well as similar pathogenic mechanisms, such as systemic inflammation. Management strategies for the care of patients with COPD and coronary artery disease are similar to those without COPD, but care must be given to address their respiratory limitations. Arrhythmias occur frequently in patients with COPD, but are rarely fatal and can generally be treated medically. Use of beta-blockers in the management of cardiac disease, while a theoretical concern in patients with increased airway resistance, is generally safe with the use of cardioselective agents.

摘要

慢性阻塞性肺疾病(COPD)的心脏表现多种多样。右心室功能障碍和肺血管疾病的损害众所周知,会使COPD的临床病程复杂化,并与生存率呈负相关。COPD中肺血管疾病的发病机制可能是多因素的,与气体交换和血管生物学的改变、肺血管的结构变化以及机械因素有关。目前有几种方法可用于评估COPD中的肺血管疾病,但右心导管检查仍是金标准。虽然除了氧气之外,没有其他特定疗法被普遍接受用于治疗该人群的肺动脉高压,但人们对特定的肺血管扩张剂重新产生了兴趣。COPD与冠状动脉疾病经常并存。这种关联可能与共同的危险因素以及相似的致病机制有关,如全身炎症。COPD和冠状动脉疾病患者的护理管理策略与无COPD患者相似,但必须注意解决他们的呼吸限制问题。心律失常在COPD患者中经常发生,但很少致命,通常可以通过药物治疗。在心脏病管理中使用β受体阻滞剂,虽然理论上对气道阻力增加的患者是一个问题,但使用心脏选择性药物通常是安全的。

相似文献

1
Cardiac disease in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的心脏疾病
Proc Am Thorac Soc. 2008 May 1;5(4):543-8. doi: 10.1513/pats.200708-142ET.
3
[Chronic obstructive pulmonary disease and heart failure].[慢性阻塞性肺疾病与心力衰竭]
Arch Bronconeumol. 2009 Aug;45(8):387-93. doi: 10.1016/j.arbres.2008.05.011. Epub 2009 Jul 12.
8
[How to manage the patients with hypoxic pulmonary hypertension?].
Pol Merkur Lekarski. 2005 Oct;19(112):567-70.

引用本文的文献

1
Causes of ventilatory inefficiency in lung resection candidates.肺切除候选者通气效率低下的原因。
ERJ Open Res. 2025 Mar 24;11(2). doi: 10.1183/23120541.00792-2024. eCollection 2025 Mar.
2
Hyperkalemia Is an Underestimated Risk Factor in COPD.高钾血症是慢性阻塞性肺疾病中一个被低估的风险因素。
Int J Chron Obstruct Pulmon Dis. 2025 Mar 15;20:723-734. doi: 10.2147/COPD.S490620. eCollection 2025.

本文引用的文献

6
9
Corticosteroids and the risk of atrial fibrillation.皮质类固醇与心房颤动风险
Arch Intern Med. 2006 May 8;166(9):1016-20. doi: 10.1001/archinte.166.9.1016.
10
Brain natriuretic peptide is a prognostic parameter in chronic lung disease.脑钠肽是慢性肺病的一项预后参数。
Am J Respir Crit Care Med. 2006 Apr 1;173(7):744-50. doi: 10.1164/rccm.200510-1545OC. Epub 2006 Jan 13.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验